Literature DB >> 16809970

Olanzapine use in adolescent anorexia nervosa.

K Dennis1, D Le Grange, J Bremer.   

Abstract

Several case reports and open label trials describe olanzapine in the treatment of anorexia nervosa (AN). We report 5 adolescents with AN who received olanzapine in addition to psychotherapy for their eating disorder. Body mass index (BMI) of each case increased while on olanzapine. At doses of 5 mg per day and above, patients reported decreased anxiety around eating, improved sleep, and decreased rumination about food and body concerns. Morning sedation was the most commonly reported adverse effect. Olanzapine appeared to be useful in addition to psychotherapy for these adolescents. This report augments a limited literature on the treatment of this disorder, and an almost nonexistent literature specific to pharmacotherapy for adolescents with AN.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809970     DOI: 10.1007/bf03327760

Source DB:  PubMed          Journal:  Eat Weight Disord        ISSN: 1124-4909            Impact factor:   4.652


  11 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  Altered response to meta-chlorophenylpiperazine in anorexia nervosa: support for a persistent alteration of serotonin activity after short-term weight restoration.

Authors:  G K Frank; W H Kaye; T E Weltzin; J Perel; H Moss; C McConaha; C Pollice
Journal:  Int J Eat Disord       Date:  2001-07       Impact factor: 4.861

3.  Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases.

Authors:  C Mehler; C Wewetzer; U Schulze; A Warnke; F Theisen; R W Dittmann
Journal:  Eur Child Adolesc Psychiatry       Date:  2001-06       Impact factor: 4.785

4.  Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa.

Authors:  Naresh Mondraty; C Laird Birmingham; Stephen Touyz; Viktoria Sundakov; Lucy Chapman; Pierre Beumont
Journal:  Australas Psychiatry       Date:  2005-03       Impact factor: 1.369

5.  Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride.

Authors:  W Vandereycken
Journal:  Br J Psychiatry       Date:  1984-03       Impact factor: 9.319

6.  Case reports of olanzapine treatment of anorexia nervosa.

Authors:  M C La Via; N Gray; W H Kaye
Journal:  Int J Eat Disord       Date:  2000-04       Impact factor: 4.861

Review 7.  Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics?

Authors:  Peter Bosanac; Trevor Norman; Graham Burrows; Peter Beumont
Journal:  Aust N Z J Psychiatry       Date:  2005-03       Impact factor: 5.744

Review 8.  Serotonin activity in anorexia and bulimia nervosa: relationship to the modulation of feeding and mood.

Authors:  W H Kaye; T E Weltzin
Journal:  J Clin Psychiatry       Date:  1991-12       Impact factor: 4.384

9.  Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline.

Authors:  K A Halmi; E Eckert; T J LaDu; J Cohen
Journal:  Arch Gen Psychiatry       Date:  1986-02

10.  Olanzapine in the treatment of anorexia nervosa: an open label trial.

Authors:  Pauline S Powers; Carlos A Santana; Yvonne S Bannon
Journal:  Int J Eat Disord       Date:  2002-09       Impact factor: 4.861

View more
  10 in total

1.  Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa.

Authors:  Vikas Duvvuri; Taya Cromley; Megan Klabunde; Kerri Boutelle; Walter H Kaye
Journal:  Int J Eat Disord       Date:  2011-02-22       Impact factor: 4.861

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

3.  Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice.

Authors:  Stephanie J Klenotich; Mariel P Seiglie; Matthew S McMurray; Jamie D Roitman; Daniel Le Grange; Priya Dugad; Stephanie C Dulawa
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

4.  A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study.

Authors:  Jennifer Hagman; Jane Gralla; Eric Sigel; Swan Ellert; Mindy Dodge; Rick Gardner; Teri O'Lonergan; Guido Frank; Marianne Z Wamboldt
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-08-05       Impact factor: 8.829

5.  Melanin-concentrating hormone is necessary for olanzapine-inhibited locomotor activity in male mice.

Authors:  Melissa J S Chee; Nicholas Douris; Avery B Forrow; Arnaud Monnard; Shuangyu Lu; Stephen E Flaherty; Andrew C Adams; Eleftheria Maratos-Flier
Journal:  Eur Neuropsychopharmacol       Date:  2015-06-03       Impact factor: 4.600

Review 6.  Canadian practice guidelines for the treatment of children and adolescents with eating disorders.

Authors:  Jennifer Couturier; Leanna Isserlin; Mark Norris; Wendy Spettigue; Melissa Brouwers; Melissa Kimber; Gail McVey; Cheryl Webb; Sheri Findlay; Neera Bhatnagar; Natasha Snelgrove; Amanda Ritsma; Wendy Preskow; Catherine Miller; Jennifer Coelho; Ahmed Boachie; Cathleen Steinegger; Rachel Loewen; Techiya Loewen; Elizabeth Waite; Catherine Ford; Kerry Bourret; Joanne Gusella; Josie Geller; Adele LaFrance; Anick LeClerc; Jennifer Scarborough; Seena Grewal; Monique Jericho; Gina Dimitropoulos; David Pilon
Journal:  J Eat Disord       Date:  2020-02-01

7.  Sleep and its importance in adolescence and in common adolescent somatic and psychiatric conditions.

Authors:  Serge Brand; Roumen Kirov
Journal:  Int J Gen Med       Date:  2011-06-07

8.  Population pharmacokinetics of olanzapine in children.

Authors:  Anil R Maharaj; Huali Wu; Kanecia O Zimmerman; Julie Autmizguine; Rohit Kalra; Amira Al-Uzri; Catherine M T Sherwin; Stuart L Goldstein; Kevin Watt; Jinson Erinjeri; Elizabeth H Payne; Michael Cohen-Wolkowiez; Christoph P Hornik
Journal:  Br J Clin Pharmacol       Date:  2020-07-05       Impact factor: 3.716

9.  Evaluation of the Effectiveness and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Adolescents: An Open-Label Trial.

Authors:  Wendy Spettigue; Mark L Norris; Danijela Maras; Nicole Obeid; Stephen Feder; Megan E Harrison; Rebecca Gomez; Maeghan Cy Fu; Katherine Henderson; Annick Buchholz
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2018-07-01

10.  Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial.

Authors:  Wendy Spettigue; Annick Buchholz; Katherine Henderson; Stephen Feder; David Moher; Kader Kourad; Isabelle Gaboury; Mark Norris; Sheila Ledoux
Journal:  BMC Pediatr       Date:  2008-01-31       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.